Claims
- 1. A method of preparing substantially spherical granules of caffeine or acyclovir for pharmaceutical use, which method comprises introducing a mixture consisting essentially of approximately 25% caffeine or acyclovir and 75% microcrystalline cellulose as the sole excipient into a high speed agitation granulator and spraying on water or a mixture of ethanol and water as a binder solution.
- 2. A method according to claim 1 where the amount of binder solution is regulated such that granules are more suitable for administration by spoon and are generally more than 500 um in diameter.
- 3. A method according to claim 1 wherein the granules are agitated in the granulator after spraying of the binder solution to improve the spherical shape and smooth the surface of the granules.
- 4. A substantially spherical granule for pharmaceutical use produced according to the method of claim 1 comprising caffeine, pyridoxine hydrochloride or acyclovir and at least 5% microcrystalline cellulose as the sole excipient together with an optional coating.
- 5. A sachet containing a unit dose of caffeine, pyridoxine hydrochloride or acyclovir in the form of granules according to claim 4.
- 6. A method according to claim 1 wherein the granule has a diameter of 500 to 1500 um.
- 7. A method according to claim 1 wherein the granule comprises acyclovir and at least 5% microcrystalline cellulose and an optional coating.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9518465 |
Sep 1995 |
GB |
|
Parent Case Info
This is a divisional of application Ser. No. 09/029,948 filed Jul. 7, 1998, now U.S. Pat. No. 6,242,008 which is the 35 USC §371 National Stage entry of PCT International Application No. PCT/JP96/02504, filed Sep. 4, 1996.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4713245 |
Ando et al. |
Dec 1987 |
A |
5556639 |
Fielden |
Sep 1996 |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
0 608 850 |
Aug 1994 |
EP |
Non-Patent Literature Citations (1)
Entry |
Vertommen et al., European Journal of Pharmaceutics and Biopharmaceutics, vol. 40(1), pp. 32-35, (1994). |